Literature DB >> 21900396

Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype.

Liliana Soroceanu1, Lisa Matlaf, Vladimir Bezrookove, Loui Harkins, Roxanne Martinez, Mary Greene, Patricia Soteropoulos, Charles S Cobbs.   

Abstract

Human cytomegalovirus (HCMV) infections are seen often in glioblastoma multiforme (GBM) tumors, but whether the virus contributes to GBM pathogenesis is unclear. In this study, we explored an oncogenic role for the G-protein-coupled receptor-like protein US28 encoded by HCMV that we found to be expressed widely in human GBMs. Immunohistochemical and reverse transcriptase PCR approaches established that US28 was expressed in approximately 60% of human GBM tissues and primary cultures examined. In either uninfected GBM cells or neural progenitor cells, thought to be the GBM precursor cells, HCMV infection or US28 overexpression was sufficient to promote secretion of biologically active VEGF and to activate multiple cellular kinases that promote glioma growth and invasion, including phosphorylated STAT3 (p-STAT3) and endothelial nitric oxide synthase (e-NOS). Consistent with these findings, US28 overexpression increased primary GBM cell invasion in Matrigel. Notably, this invasive phenotype was further enhanced by exposure to CCL5/RANTES, a US28 ligand, associated with poor patient outcome in GBM. Conversely, RNA interference-mediated knockdown of US28 in human glioma cells persistently infected with HCMV led to an inhibition in VEGF expression and glioma cell invasion in response to CCL5 stimulation. Analysis of clinical GBM specimens further revealed that US28 colocalized in situ with several markers of angiogenesis and inflammation, including VEGF, p-STAT3, COX2, and e-NOS. Taken together, our results indicate that US28 expression from HCMV contributes to GBM pathogenesis by inducing an invasive, angiogenic phenotype. In addition, these findings argue that US28-CCL5 paracrine signaling may contribute to glioma progression and suggest that targeting US28 may provide therapeutic benefits in GBM treatment. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900396      PMCID: PMC3206211          DOI: 10.1158/0008-5472.CAN-11-0744

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.

Authors:  Kristine Dziurzynski; Jun Wei; Wei Qiao; Mustafa Aziz Hatiboglu; Ling-Yuan Kong; Adam Wu; Yongtao Wang; Daniel Cahill; Nicholas Levine; Sujit Prabhu; Ganesh Rao; Raymond Sawaya; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2011-04-13       Impact factor: 12.531

2.  Expression of nitric oxide synthase in the cerebral microvasculature after traumatic brain injury in the rat.

Authors:  C S Cobbs; A Fenoy; D S Bredt; L J Noble
Journal:  Brain Res       Date:  1997-03-21       Impact factor: 3.252

3.  The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration.

Authors:  D N Streblow; C Soderberg-Naucler; J Vieira; P Smith; E Wakabayashi; F Ruchti; K Mattison; Y Altschuler; J A Nelson
Journal:  Cell       Date:  1999-11-24       Impact factor: 41.582

4.  Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis.

Authors:  David Maussang; Dennis Verzijl; Marijke van Walsum; Rob Leurs; Jens Holl; Olivier Pleskoff; Detlef Michel; Guus A M S van Dongen; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

Review 5.  HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks.

Authors:  Henry F Vischer; Rob Leurs; Martine J Smit
Journal:  Trends Pharmacol Sci       Date:  2005-12-13       Impact factor: 14.819

6.  Using DNA microarray to study human cytomegalovirus gene expression.

Authors:  Shaojun Yang; Saleena Ghanny; Weijia Wang; Anthony Galante; Walter Dunn; Fenyong Liu; Patricia Soteropoulos; Hua Zhu
Journal:  J Virol Methods       Date:  2005-10-13       Impact factor: 2.014

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.

Authors:  Liliana Soroceanu; Samir Kharbanda; Ruihuan Chen; Robert H Soriano; Ken Aldape; Anjan Misra; Jiping Zha; William F Forrest; Janice M Nigro; Zora Modrusan; Burt G Feuerstein; Heidi S Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

9.  Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.

Authors:  Charles S Cobbs; Liliana Soroceanu; Scott Denham; Wenyue Zhang; William J Britt; Russ Pieper; Matthias H Kraus
Journal:  J Neurooncol       Date:  2007-06-23       Impact factor: 4.130

10.  Expression of nitric oxide synthase in human central nervous system tumors.

Authors:  C S Cobbs; J E Brenman; K D Aldape; D S Bredt; M A Israel
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

View more
  69 in total

1.  Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors:  Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Cidofovir: a novel antitumor agent for glioblastoma.

Authors:  Piotr Hadaczek; Tomoko Ozawa; Liliana Soroceanu; Yasuyuki Yoshida; Lisa Matlaf; Eric Singer; Estefania Fiallos; C David James; Charles S Cobbs
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

3.  Response to "Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics".

Authors:  Charles Cobbs
Journal:  Neuro Oncol       Date:  2014-10-13       Impact factor: 12.300

4.  Methods for Studying the Function of Cytomegalovirus GPCRs.

Authors:  Christine M O'Connor; William E Miller
Journal:  Methods Mol Biol       Date:  2021

5.  Does valganciclovir have a role in glioblastoma therapy?

Authors:  Charles S Cobbs
Journal:  Neuro Oncol       Date:  2014-03       Impact factor: 12.300

Review 6.  Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?

Authors:  Henry F Vischer; Marco Siderius; Rob Leurs; Martine J Smit
Journal:  Nat Rev Drug Discov       Date:  2014-01-21       Impact factor: 84.694

Review 7.  Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.

Authors:  Silvia Montaner; Irina Kufareva; Ruben Abagyan; J Silvio Gutkind
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-22       Impact factor: 13.820

8.  The US27 gene product of human cytomegalovirus enhances signaling of host chemokine receptor CXCR4.

Authors:  Kathleen L Arnolds; Angela P Lares; Juliet V Spencer
Journal:  Virology       Date:  2013-03-13       Impact factor: 3.616

9.  Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

Authors:  Smita K Nair; Gabriel De Leon; David Boczkowski; Robert Schmittling; Weihua Xie; Janet Staats; Rebecca Liu; Laura A Johnson; Kent Weinhold; Gary E Archer; John H Sampson; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2014-03-21       Impact factor: 12.531

10.  Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer.

Authors:  Zhen-Zhai Cai; Jian-Gang Xu; Yu-Hui Zhou; Ji-Hang Zheng; Ke-Zhi Lin; Shu-Zhi Zheng; Meng-Si Ye; Yun He; Chang-Bao Liu; Zhan-Xiong Xue
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.